This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Yancovitz, M. Articles by Polsky, D. Search for Related Content PubMed PubMed Citation Articles by Yancovitz, M. Articles by Polsky, D.

JMD 2007, Vol. 9, No. 2
Copyright © 2007 American Society for Investigative Pathology & Association for Molecular Pathology

Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma

Molly Yancovitz^*, Joanne Yoon^*, Maryann Mikhail^*, Weiming Gai^*, Richard L. Shapiro, Russell S. Berman, Anna C. Pavlick^*, Paul B. Chapman, Iman Osman^* and David Polsky^*

From the Departments of Dermatology, * Surgery, and Medicine, New York University School of Medicine, New York; and the Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

Mutations in the BRAF oncogene at amino acid 600 have been reported in 40 to 70% of human metastatic melanoma tissues, and the critical role of BRAF in the biology of melanoma has been established. Sampling the blood compartment to detect the mutational status of a solid tumor represents a highly innovative advance in cancer medicine, and such an approach could have advantages over tissue-based techniques. We report the development of a fluorescence-based polymerase chain reaction (PCR) assay to detect mutant BRAF alleles in plasma. A mutant-specific PCR assay was optimized to specifically amplify the mutant BRAF allele without amplifying the wild-type allele. Experiments mixing DNA from a BRAF mutant melanoma cell line with wild-type human placental DNA in varying proportions were performed to determine the threshold of this assay and to compare it with routine DNA sequencing. The assay was then applied to tissue and plasma specimens from patients with metastatic melanoma. The assay detected 0.1 ng of mutant DNA mixed in 100 ng of wild-type DNA and was 500-fold more sensitive than DNA sequencing. The assay detected mutant BRAF alleles in plasma samples from 14 of 26 (54%) metastatic melanoma patients. These data demonstrate the feasibility of blood-based testing for BRAF mutations in metastatic melanoma patients.